All In Biotech

Drug Trial Radar · NCT06564389

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

A PHASE 1, FIRST IN HUMAN, RANDOMIZED, DOUBLE-BLIND, SPONSOROPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07832837 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

119

Planned (sponsor's estimate)

Start

Nov 5, 2024

Primary completion

Jun 2, 2027

Study completion Jun 2, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

Conditions

  • Healthy Participants
  • Atopic Dermatitis

Interventions

  • PF-07832837Drug

    escalated doses of PF-07832837

  • PlaceboOther

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)Time frame: Baseline up to Day 35
  2. Number of Participants with Clinically significant Laboratory Abnormalities Following SADTime frame: Baseline up to Day 35
  3. Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SADTime frame: Baseline up to Day 35
  4. Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SADTime frame: Baseline up to Day 35
  5. Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SADTime frame: Day 1
  6. Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD)Time frame: Baseline up to Day 50
  7. Number of Participants with Clinically significant Laboratory Abnormalities Following MADTime frame: Baseline up to Day 50
  8. Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MADTime frame: Baseline up to Day 50
  9. Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD)Time frame: Baseline up to Day 80
  10. Number of Participants with Clinically significant Laboratory Abnormalities in participants with ADTime frame: Baseline up to Day 80
  11. Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with ADTime frame: Baseline up to Day 78

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC

    Anaheim, California · Recruiting

  • TCR Medical Corporation

    San Diego, California · Recruiting

  • Miami Dermatology and Laser Research

    Miami, Florida · Recruiting

  • Revival Research Institute, LLC

    Troy, Michigan · Recruiting

  • Paddington Testing Company

    Philadelphia, Pennsylvania · Recruiting

  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

    Lodz, Łódź Voivodeship, Poland · Not yet recruiting

  • Centrum Medyczne Angelius Provita

    Katowice, Silesian Voivodeship, Poland · Not yet recruiting

  • Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej Królicki

    Szczecin, West Pomeranian Voivodeship, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.